Prostate cancer: Promising biomarkers related to aggressive disease;Cáncer de próstata: biomarcadores prometedores relacionados con la enfermedad agresiva

Actas Urologicas Espanolas

Volumn 36, Issue 8, 2012, Pages 484-490

  Ribeiro Da Silva, M N ^a   Tobias Machado, M ^a   Lima Pompeo, A C ^a   Reis, L O ^b   Da Silva Pinhal, M A ^a  

^a FACULDADE DE MEDICINA DO ABC   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Aggressiveness; Markers; Prognosis; Prostate

Indexed keywords

EID: 84865512818     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acuro.2011.11.017     Document Type: Short Survey

References (66)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics: 2010 CA Cancer J Clin 60 2010 277 300
2. Reis LO. Old issues and new perspectives on prostate cancer hormonal therapy: the molecular substratum. Med Oncol. 2011; [Epub ahead of print]. DOI: 10.1007/s12032-011-9991-z; PMID: 21626233.
3. B.J. Feldman, and D. Feldman The development of androgen-independent prostate cancer Nat Rev Cancer 1 2001 34 45
4. A. Gugliotta, U. Ferreira, L.O. Reis, W.E. Matheus, F. Denardi, and R. Mamprim Stopiglia Satisfaction analysis in men presenting with localized prostate cancer treated with radical prostatectomy or radiotherapy: psychological and social aspects Actas Urol Esp 32 2008 411 416
5. L.O. Reis, E.L. Zani, A. Billis, A. Prudente, F. Denardi, and U. Ferreira The triple clinicopathologic features to seminal vesicle-sparing radical prostatectomy J Endourol 24 2010 1535 1539
6. J. Hernandez, and I.M. Thompson Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker Cancer 101 2004 894 904
7. L.O. Reis, E.L. Zani, J.C. Alonso, F.A. Simões, R.F. Rejowski, and U. Ferreira Does the criterion for prostate biopsy indication impact its accuracy? A prospective population-based outpatient clinical setting study Actas Urol Esp 35 2011 10 14
8. A.S. Neto, M. Tobias-Machado, M.L. Wroclawski, F.L. Fonseca, A.C. Pompeo, and A. Del Giglio Molecular oncogenesis of prostate adenocarcinoma: role of the human epidermal growth factor receptor 2 (HER-2/neu) Tumori 96 2010 645 649
9. L.O. Reis, T.C. Pereira, I. Lopes-Cendes, and U. Ferreira MicroRNAs: a new paradigm on molecular urological oncology Urology 76 2010 Sep 521 527
10. O.J. Halvorsen, J. Høstmark, S. Haukaas, P.A. Høisaeter, and L.A. Akslen Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma Cancer 88 2000 416 424
11. S.M. Henshall, D.I. Quinn, C.S. Lee, D.R. Head, D. Golovsky, and P.C. Brenner Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer Cancer Res 61 2001 423 427
12. J. Rigaud, R. Tiguert, M. Decobert, H. Hovington, E. Latulippe, and J. Laverdiere Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy Prostate 58 2004 269 276
13. C. Cordon-Cardo Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma J Natl Cancer Inst 90 1998 1284 1291
14. S.J. Freedland, F. deGregorio, J.C. Sacoolidge, Y.I. Elshimali, G.S. Csathy, and F. Dorey Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy J Urol 169 2003 1325 1330
15. M.A. Kuczyk, C. Bokemeyer, J. Hartmann, J. Schubach, C. Walter, and S. Machtens Predictive value of altered p27Kip1 and p21WAF/Cip1 protein expression for the clinical prognosis of patients with localized prostate cancer Oncol Rep 8 2001 1401 1407
16. J. Tsihlias, L.R. Kapusta, G. DeBoer, I. Morava-Protzner, I. Zbieranowski, and N. Bhattacharya Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma Cancer Res 58 1998 542 548
17. R. Berger, D.I. Lin, M. Nieto, E. Sicinska, L.A. Garraway, and H. Adams Androgen-dependent regulation of Her-2/neu in prostate cancer cells Cancer Res 66 2006 5723 5728
18. A.S. Neto, M. Tobias-Machado, M.L. Wroclawski, F.L. Fonseca, G.K. Teixeira, and R.D. Amarante Her-2/neu expression in prostate adenocarcinoma: a systematic review and meta-analysis J Urol 184 2010 842 850
19. J. Barba, X. Brugarolas, E. Tolosa, A. Rincón, L. Romero, and D. Rosell Time-influencing factors for biochemical progression following radical prostatectomy Actas Urol Esp 35 2011 201 207
20. J.D. Oxley, M.H. Winkler, K. Parry, S. Brewster, C. Abbott, and D.A. Gillatt p53 and bcl-2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy BJU Int 89 2002 27 32
21. D.J. Grignon, R. Caplan, F.H. Sarkar, C.A. Lawton, E.H. Hammond, and M.V. Pilepich p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610 J Natl Cancer Inst 89 1997 158 165
22. T.T. Wu, Y.S. Hsu, J.S. Wang, Y.H. Lee, and J.K. Huang The role of p53: bcl-2 and E-cadherin expression in predicting biochemical relapse for organ confined prostate cancer in Taiwan J Urol 170 2003 78 81
23. L.Y. Khor, J. Moughan, T. Al-Saleem, E.H. Hammond, V. Venkatesan, and S.A. Rosenthal Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02 Clin Cancer Res 13 2007 3585 3590
24. M. Tobias-Machado, F. Fonseca, A.P. Fantinato, I. Bendit, and M.L. Wroclawski Cytokeratin 19 expression by reverse transcriptase-polymerase chain reaction in the peripheral blood of prostate cancer patients Tumori 91 2005 248 252
25. A.P. Fantinato, M. Tobias-Machado, F. Fonseca, J.L. Pinto, M.L. Wroclawski, and E. Wroclawski Her2/neu expression by reverse transcriptase-polymerase chain reaction in the peripheral blood of prostate cancer patients Tumori 93 2007 467 472
26. A. Lopergolo, and N. Zaffaroni Biomolecular markers of outcome prediction in prostate cancer Cancer 115 13 Suppl 2009 3058 3067
27. I.L. Rosner, L. Ravindranath, B. Furusato, Y. Chen, C. Gao, and J. Cullen Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy Urology 70 2007 1225 1229
28. S.F. Shariat, K. Bensalah, J.A. Karam, C.G. Roehrborn, A. Gallina, and Y. Lotan Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer Clin Cancer Res 13 18 Pt 1 2007 5377 5384
29. D.R. Rhodes, M.G. Sanda, A.P. Otte, A.M. Chinnaiyan, and M.A. Rubin Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer J Natl Cancer Inst 95 2003 661 668
30. K. Gravdal, O.J. Halvorsen, S.A. Haukaas, and L.A. Akslen A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer Clin Cancer Res 13 2007 7003 7011
31. R.K. Nam, L. Sugar, W. Yang, S. Srivastava, L.H. Klotz, and L.Y. Yang Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer Br J Cancer 97 2007 1690 1695
32. G. Attard, J. Clark, L. Ambroisine, G. Fisher, G. Kovacs, and P. Flohr Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer Oncogene 27 2008 253 263
33. A. Fernández-Serra, J. Rubio-Briones, Z. García-Casado, E. Solsona, and J.A. López-Guerrero Prostate cancer: the revolution of the fusion genes Actas Urol Esp 35 2011 420 428
34. R. Mehra, S.A. Tomlins, R. Shen, O. Nadeem, and L. Wang Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer Mod Pathol 20 2007 538 544
35. P.J. Bastian, J. Ellinger, L.C. Heukamp, P. Kahl, S.C. Müller, and A. Von Rücker Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy Eur Urol 51 2007 665 674
36. J. Ellinger, P.J. Bastian, T. Jurgan, K. Biermann, P. Kahl, and L.C. Heukamp CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer Urology 71 2008 161 167
37. R. Henrique, F.R. Ribeiro, D. Fonseca, M.O. Hoque, A.L. Carvalho, and V.L. Costa High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients Clin Cancer Res 13 2007 6122 6129
38. E. Rosenbaum, M.O. Hoque, Y. Cohen, M. Zahurak, M.A. Eisenberger, and J.I. Epstein Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy Clin Cancer Res 11 2005 8321 8325
39. L.T. Amundadottir, P. Sulem, J. Gudmundsson, A. Helgason, A. Baker, and B.A. Agnarsson A common variant associated with prostate cancer in European and African populations Nat Genet 38 2006 652 658
40. R.A. Eeles, Z. Kote-Jarai, G.G. Giles, A.A. Olama, M. Guy, and S.K. Jugurnauth Multiple newly identified loci associated with prostate cancer susceptibility Nat Genet 40 2008 316 321
41. J. Gudmundsson, P. Sulem, A. Manolescu, L.T. Amundadottir, D. Gudbjartsson, A. Helgason, and T. Rafnar Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24 Nat Genet 39 2007 631 637
42. J. Gudmundsson, P. Sulem, V. Steinthorsdottir, J.T. Bergthorsson, G. Thorleifsson, and A. Manolescu Two variants on chromosome 17 confer prostate cancer risk: and the one in TCF2 protects against type 2 diabetes Nat Genet 39 2007 977 983
43. G. Thomas, K.B. Jacobs, M. Yeager, P. Kraft, S. Wacholder, and N. Orr Multiple loci identified in a genome-wide association study of prostate cancer Nat Genet 40 2008 310 315
44. M. Yeager, N. Orr, R.B. Hayes, K.B. Jacobs, P. Kraft, and S. Wacholder Genome-wide association study of prostate cancer identifies a second risk locus at 8q24 Nat Genet 39 2007 645 649
45. B.T. Helfand, S. Loeb, J.J. Meeks, A.J. Fought, D. Kan, and W.J. Catalona Pathological outcomes associated with the 17q prostate cancer risk variants J Urol 181 2009 2502 2507
46. J. Morote, J. Del Amo, A. Borque, E. Ars, C. Hernández, and F. Herranz Improved prediction of biochemical recurrence after radical prostatectomy by genetic polymorphisms J Urol 184 2010 506 511
47. J. Ahn, A.S. Kibel, J.Y. Park, T.R. Rebbeck, H. Rennert, and J.L. Stanford Prostate Cancer Predisposition Loci and Risk of Metastatic Disease and Prostate Cancer Recurrence Clin Cancer Res 17 2011 1075 1081
48. T. Sun, L.G. Mary, W.K. Oh, M.L. Freedman, M. Pomerantz, and K.J. Pienta Inherited Variants in the Chemokine CCL2 Gene and Prostate Cancer Aggressiveness in a Caucasian Cohort Clin Cancer Res 17 2011 1546 1552
49. B.Y. Bao, J.B. Pao, C.N. Huang, Y.S. Pu, T.Y. Chang, and Y.H. Lan Polymorphisms inside microRNAs and microRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy Clin Cancer Res 17 2011 928 936
50. Z. Panteleakou, P. Lembessis, A. Sourla, N. Pissimissis, A. Polyzos, and C. Deliveliotis Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance Mol Med 15 2009 101 114
51. T. Okegawa, K. Nutahara, and E. Higashihara Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer Int J Urol 17 2010 466 475
52. M.C. Miller, G.V. Doyle, and L.W. Terstappen Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer J Oncol 2010 2010 617421
53. O.B. Goodman Jr., L.M. Fink, J.T. Symanowski, B. Wong, B. Grobaski, and D. Pomerantz Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors Cancer Epidemiol Biomarkers Prev 18 2009 1904 1913
54. L.S. Marks, Y. Fradet, I.L. Deras, A. Blase, J. Mathis, and S.M. Aubin PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy Urology 69 2007 532 535
55. I.L. Deras, S.M. Aubin, A. Blase, J.R. Day, S. Koo, and A.W. Partin PCA3: a molecular urine assay for predicting prostate biopsy outcome J Urol 179 2008 1587 1592
56. E.J. Whitman, J. Groskopf, A. Ali, Y. Chen, A. Blase, and B. Furusato PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume J Urol 180 2008 1975 1978 discussion 1978-9
57. M.A. Liss, R. Santos, K. Osann, A. Lau, T.E. Ahlering, and D.K. Ornstein PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocols World J Urol 2010
58. J.J. Tosoian, S. Loeb, A. Kettermann, P. Landis, D.J. Elliot, and J.I. Epstein Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program J Urol 183 2010 534 538
59. J. Rubio-Briones, A. Fernández-Serra, M. Ramírez, L. Rubio, A. Collado, and J. Casanova Outcomes of Expanded Use of PCA3 Testing in a Spanish Population with Clinical Suspicion of Prostate Cancer Actas Urol Esp 35 2011 589 596
60. L.O. Reis, L.F. Vieira, E.L. Zani, F. Denardi, L.C. De Oliveira, and U. Ferreira Assessment of serum chromogranin-A as prognostic factor in high-risk prostate cancer J Investig Med 58 2010 957 960
61. Z. Ma, N. Tsuchiya, T. Yuasa, M. Huang, T. Obara, and S. Narita Clinical significance of polymorphism and expression of chromogranin-A and endothelin-1 in prostate cancer J Urol 184 2010 1182 1188
62. M.W. Kattan, S.F. Shariat, B. Andrews, K. Zhu, E. Canto, and K. Matsumoto The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer J Clin Oncol 21 2003 3573 3579
63. S.F. Shariat, S. Park, Q.D. Trinh, C.G. Roehrborn, K.M. Slawin, and P.I. Karakiewicz Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms J Urol 178 4 Pt 1 2007 1229 1236
64. A.J. Stephenson, A. Smith, M.W. Kattan, J. Satagopan, V.E. Reuter, and P.T. Scardino Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy Cancer 104 2005 290 298
65. L.O. Reis, A.D. Sasse, W.E. Matheus, F. Denardi, R.M. Stopiglia, and M.M. da Silva Prostate cancer: evidence based clinical practice Actas Urol Esp 33 2009 344 350
66. F. Gómez-Veiga, A. Alcaraz-Asensio, J. Burgos-Revilla, and J.M. Cózar-Olmo Advances in uro-oncology OncoForum: the best of 2010 Actas Urol Esp 35 2011 315 324